ES2181670T3 - Peptidos que conservan una actividad similar a la de la tromboespondina y su utilizacion terapeutica. - Google Patents

Peptidos que conservan una actividad similar a la de la tromboespondina y su utilizacion terapeutica.

Info

Publication number
ES2181670T3
ES2181670T3 ES92107774T ES92107774T ES2181670T3 ES 2181670 T3 ES2181670 T3 ES 2181670T3 ES 92107774 T ES92107774 T ES 92107774T ES 92107774 T ES92107774 T ES 92107774T ES 2181670 T3 ES2181670 T3 ES 2181670T3
Authority
ES
Spain
Prior art keywords
thrombospondine
peptides
keep
therapeutic use
activity similar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92107774T
Other languages
English (en)
Inventor
Jacob Eyal
George Paul Tuszynski
Bruce King Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WR Grace and Co Conn
WR Grace and Co
Philadelphia Health and Education Corp
Original Assignee
WR Grace and Co Conn
WR Grace and Co
Philadelphia Health and Education Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WR Grace and Co Conn, WR Grace and Co, Philadelphia Health and Education Corp filed Critical WR Grace and Co Conn
Application granted granted Critical
Publication of ES2181670T3 publication Critical patent/ES2181670T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PROPORCIONAN COMPUESTOS Y COMPOSICIONES QUE COMPRENDEN FRAGMENTOS Y ANALOGOS SINTETICOS DE TROMBOSPONDINA HUMANA JUNTO A METODOS PARA SU UTILIZACION COMO AGENTES SIMILARES A LA TROMBOSPONDINA.
ES92107774T 1991-05-22 1992-05-08 Peptidos que conservan una actividad similar a la de la tromboespondina y su utilizacion terapeutica. Expired - Lifetime ES2181670T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70525591A 1991-05-22 1991-05-22

Publications (1)

Publication Number Publication Date
ES2181670T3 true ES2181670T3 (es) 2003-03-01

Family

ID=24832676

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92107774T Expired - Lifetime ES2181670T3 (es) 1991-05-22 1992-05-08 Peptidos que conservan una actividad similar a la de la tromboespondina y su utilizacion terapeutica.

Country Status (7)

Country Link
US (1) US5654277A (es)
EP (1) EP0514721B1 (es)
JP (2) JP3706151B2 (es)
AU (1) AU1636492A (es)
CA (1) CA2063055A1 (es)
DE (1) DE69232716T2 (es)
ES (1) ES2181670T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
DE4203545A1 (de) * 1992-02-07 1993-08-12 Behringwerke Ag Spezifische antikoerper gegen aktivierte plaettchen, ihre herstellung und ihre verwendung in diagnose und therapie
WO1996033218A1 (en) * 1995-04-21 1996-10-24 Allelix Biopharmaceuticals Inc. Anti-haemorrhagic peptides
AU5699996A (en) * 1995-06-02 1996-12-18 Allelix Biopharmaceuticals Inc. Anti-inflammatory thrombospondin-derived peptides
WO1999011268A1 (en) * 1997-08-28 1999-03-11 Yoshitomi Pharmaceutical Industries, Ltd. Neovascularization promoters and neovascularization potentiators
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
EP1077995A1 (en) * 1998-05-22 2001-02-28 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CN1297930A (zh) * 1999-11-29 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人凝血栓蛋白30和编码这种多肽的多核苷酸
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7655411B2 (en) * 2002-08-23 2010-02-02 W2 Holdings, Inc. Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
US9708371B2 (en) * 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
EP1069137A1 (en) * 1990-09-24 2001-01-17 W.R. Grace & Co.-Conn. Peptides having thrombospondin-like activity and their therapeutic use

Also Published As

Publication number Publication date
EP0514721A1 (en) 1992-11-25
US5654277A (en) 1997-08-05
DE69232716T2 (de) 2002-11-28
CA2063055A1 (en) 1992-11-23
AU1636492A (en) 1992-11-26
JP3706151B2 (ja) 2005-10-12
DE69232716D1 (de) 2002-09-12
EP0514721B1 (en) 2002-08-07
JPH05178757A (ja) 1993-07-20
JP2005272480A (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
ES2181670T3 (es) Peptidos que conservan una actividad similar a la de la tromboespondina y su utilizacion terapeutica.
ES2003605A6 (es) Procedimiento de obtencion de una composicion farmaceutica particularmente dermatologica o cosmetica a base de fases laminares lipidicas hidratas o de liposomas que contienen un retinoide o un analogo estructural de dicho retinoide tal como un carotenoide.
NO831575L (no) Menneskevev-plasminogenaktivator
BR8803899A (pt) Composicao para cuidados da pele
ES2152710T3 (es) Preparados cosmeticos para aplicacion topica que contienen extractos de phyllanthus emblica y centella asiatica y/o bacopa monnieri.
ES2120274T3 (es) Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion.
ES2167592T3 (es) Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada.
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
ES2116986T3 (es) Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello.
ES2176795T3 (es) Composiciones a base de esfingomielanasa y su utilizacion.
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
ES2176487T3 (es) Composiciones cosmeticas y/o farmaceuticas antipruriginosas compuestas de uno o varios anestesicos locales suaves y uno o varios astringentes.
ES2153053T3 (es) Liposomas de eter-lipido y su uso terapeutico.
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES2045479T3 (es) Metodo cosmetico que utiliza un extracto de las partes aereas de cichorium intybus l.
MX197183A (es) Activador de plasminogeno de tejido humano
ES2059721T3 (es) Composicion para el tratamiento de la piel.
IE791804L (en) Medicated animal feed
ES2038270T3 (es) Preparaciones topicas sebosupresoras.
AR225048A1 (es) Nuevas nikkomicinas de propiedades plaguicidas,y desprovistas de actividad terapeutica,procedimientos para producirlas y composiciones plaguicidas que las contienen
ES2059320T3 (es) Nuevos diarilalcanoides que tienen actividad como inhibidores de lipoxigenasa.
AR004052A1 (es) Una composición cosmética o farmacéutica que comprende un agonista beta-adrenergico
PT817625E (pt) Composicoes para o tratamento de pele fotodanificada, compreendendo um antagonista de rar-alfa e um retinoide multi-selectivo
ES2169420T3 (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para tratar enfermedades proliferativas.